Structural basis for eculizumab-mediated inhibition of the complement terminal pathway

Journal of Immunology

Volumn 197, Issue 1, 2016, Pages 337-344

  Schatz Jakobsen, Janus Asbjørn ^a   Zhang, Yuchun ^b   Johnson, Krista ^b   Neill, Alyssa ^b   Sheridan, Douglas ^b   Andersen, Gregers Rom ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b ALEXION PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5; ECULIZUMAB; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGLOBULIN; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ANIMAL CELL; ARTICLE; COMPLEMENT INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HEMOLYSIS ASSAY; HUMAN; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN POLYMORPHISM; ANIMAL; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; DNA MUTATIONAL ANALYSIS; GENETICS; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; IMMUNOLOGY; METABOLISM; MUTATION; PHYLOGENY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT C5; CRYSTALLOGRAPHY, X-RAY; DNA MUTATIONAL ANALYSIS; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MUTATION; PHYLOGENY; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84975295524     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600280     Document Type: Article

References (30)

1. Takata, Y., T. Kinoshita, H. Kozono, J. Takeda, E. Tanaka, K. Hong, and K. Inoue. 1987. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway. J. Exp. Med. 165: 1494-1507.
2. Medicus, R. G., O. Götze, and H. J. Muller-Eberhard. 1976. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J. Exp. Med. 144: 1076-1093.
3. Kinoshita, T., Y. Takata, H. Kozono, J. Takeda, K. S. Hong, and K. Inoue. 1988. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. J. Immunol. 141: 3895-3901.
4. Klos, A., E. Wende, K. J. Wareham, and P. N. Monk. 2013. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65: 500-543.
5. Götze, O., and H. J. Muller-Eberhard. 1970. Lysis of erythrocytes by complement in the absence of antibody. J. Exp. Med. 132: 898-915.
6. Lachmann, P. J., and R. A. Thompson. 1970. Reactive lysis: The complementmediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J. Exp. Med. 131: 643-657.
7. Moskovich, O., and Z. Fishelson. 2007. Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex. J. Biol. Chem. 282: 29977-29986.
8. Podack, E. R., W. P. Kolb, and H. J. Muller-Eberhard. 1978. The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J. Immunol. 120: 1841-1848.
9. Tschopp, J., and L. E. French. 1994. Clusterin: modulation of complement function. Clin. Exp. Immunol. 97(Suppl 2): 11-14.
10. Heinen, S., A. Hartmann, N. Lauer, U. Wiehl, H. M. Dahse, S. Schirmer, K. Gropp, T. Enghardt, R. Wallich, S. Hälbich, et al. 2009. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 114: 2439-2447.
11. Rollins, S. A., and P. J. Sims. 1990. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J. Immunol. 144: 3478-3483.
12. Bessler, M., P. J. Mason, P. Hillmen, T. Miyata, N. Yamada, J. Takeda, L. Luzzatto, and T. Kinoshita. 1994. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 13: 110-117.
13. Takeda, J., T. Miyata, K. Kawagoe, Y. Iida, Y. Endo, T. Fujita, M. Takahashi, T. Kitani, and T. Kinoshita. 1993. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73: 703-711.
14. Noris, M., and G. Remuzzi. 2009. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361: 1676-1687.
15. Thomas, T. C., S. A. Rollins, R. P. Rother, M. A. Giannoni, S. L. Hartman, E. A. Elliott, S. H. Nye, L. A. Matis, S. P. Squinto, and M. J. Evans. 1996. Inhibition of complement activity by humanized anti-C5 antibody and singlechain Fv. Mol. Immunol. 33: 1389-1401.
16. Evans,M. J., L. A. Matis, E. E.Mueller, S. H. Nye, S. Rollins, R. P. Rother, J. P. Springborn, S. P. Squinto, T. C. Thomas, and J. A. Wilkins, inventors. 2002. C5-specific antibodies for the treatment of inflammatory diseases. United States Patent application US 08/487,283, Publication Number US6355245 B1. 12 Mar 2002.
17. Nishimura, J., M. Yamamoto, S. Hayashi, K. Ohyashiki, K. Ando, A. L. Brodsky, H. Noji, K. Kitamura, T. Eto, T. Takahashi, et al. 2014. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med. 370: 632-639.
18. Sottrup-Jensen, L., and G. R. Andersen. 2014. Purification of human complement protein C5. Methods Mol. Biol. 1100: 93-102.
19. Brodersen, D. E., G. R. Andersen, and C. B. Andersen. 2013. Mimer: an automated spreadsheet-based crystallization screening system. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 69: 815-820.
20. Kabsch, W. 2010. Xds. Acta Crystallogr. D Biol. Crystallogr. 66: 125-132.
21. McCoy, A. J., R. W. Grosse-Kunstleve, L. C. Storoni, and R. J. Read. 2005. Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61: 458-464.
22. Jones, T. A., J. Y. Zou, S. W. Cowan, and M. Kjeldgaard. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47: 110-119.
23. Emsley, P., B. Lohkamp, W. G. Scott, and K. Cowtan. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66: 486-501.
24. Adams, P. D., P. V. Afonine, G. Bunkóczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, et al. 2010. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66: 213-221.
25. Chen, V. B., W. B. Arendall, III, J. J. Headd, D. A. Keedy, R. M. Immormino, G. J. Kapral, L. W. Murray, J. S. Richardson, and D. C. Richardson. 2010. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66: 12-21.
26. Laursen, N. S., K. R. Andersen, I. Braren, E. Spillner, L. Sottrup-Jensen, and G. R. Andersen. 2011. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J. 30: 606-616.
27. Fredslund, F., N. S. Laursen, P. Roversi, L. Jenner, C. L. Oliveira, J. S. Pedersen, M. A. Nunn, S. M. Lea, R. Discipio, L. Sottrup-Jensen, and G. R. Andersen. 2008. Structure of and influence of a tick complement inhibitor on human complement component 5. Nat. Immunol. 9: 753-760.
28. Laursen, N. S., N. Gordon, S. Hermans, N. Lorenz, N. Jackson, B. Wines, E. Spillner, J. B. Christensen, M. Jensen, F. Fredslund, et al. 2010. Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 107: 3681-3686.
29. Jore, M. M., S. Johnson, D. Sheppard, N. M. Barber, Y. I. Li, M. A. Nunn, H. Elmlund, and S. M. Lea. 2016. Structural basis for therapeutic inhibition of complement C5. Nat. Struct. Mol. Biol. DOI: 10.1038/nsmb.3196.
30. Krissinel, E., and K. Henrick. 2007. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372: 774-797.